JP2025516659A5 - - Google Patents
Info
- Publication number
- JP2025516659A5 JP2025516659A5 JP2024566662A JP2024566662A JP2025516659A5 JP 2025516659 A5 JP2025516659 A5 JP 2025516659A5 JP 2024566662 A JP2024566662 A JP 2024566662A JP 2024566662 A JP2024566662 A JP 2024566662A JP 2025516659 A5 JP2025516659 A5 JP 2025516659A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- nucleic acid
- optionally substituted
- oligonucleotide
- heteroatoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263341407P | 2022-05-12 | 2022-05-12 | |
| US63/341,407 | 2022-05-12 | ||
| PCT/US2023/022142 WO2023220440A1 (en) | 2022-05-12 | 2023-05-12 | Oligonucleotide compositions and methods thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025516659A JP2025516659A (ja) | 2025-05-30 |
| JP2025516659A5 true JP2025516659A5 (cg-RX-API-DMAC10.html) | 2026-05-19 |
Family
ID=88731022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024566662A Pending JP2025516659A (ja) | 2022-05-12 | 2023-05-12 | オリゴヌクレオチド組成物及びその方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250302995A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4522744A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025516659A (cg-RX-API-DMAC10.html) |
| CN (1) | CN119452084A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023268503A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3253279A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023220440A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014010250A1 (en) | 2012-07-13 | 2014-01-16 | Chiralgen, Ltd. | Asymmetric auxiliary group |
| EP3094728B1 (en) | 2014-01-16 | 2022-03-09 | Wave Life Sciences Ltd. | Chiral design |
| CN117965536A (zh) | 2015-07-22 | 2024-05-03 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| MA46427A (fr) | 2015-10-09 | 2018-08-15 | Wave Life Sciences Ltd | Compositions d'oligonucléotides et procédés associés |
| US11013757B2 (en) | 2016-06-03 | 2021-05-25 | Wave Life Sciences Ltd. | Oligonucleotides, compositions and methods thereof |
| WO2018098264A1 (en) | 2016-11-23 | 2018-05-31 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
| WO2018237194A1 (en) | 2017-06-21 | 2018-12-27 | Wave Life Sciences Ltd. | Compounds, compositions and methods for synthesis |
| CN111108096A (zh) | 2017-09-18 | 2020-05-05 | 波涛生命科学有限公司 | 寡核苷酸制备技术 |
| JP2021521140A (ja) | 2018-04-12 | 2021-08-26 | ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. | オリゴヌクレオチド組成物及びその使用方法 |
| CA3098624A1 (en) | 2018-05-11 | 2019-11-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| AU2020241559A1 (en) | 2019-03-20 | 2021-11-11 | Wave Life Sciences Ltd. | Technologies useful for oligonucleotide preparation |
| MX2021012981A (es) | 2019-04-25 | 2022-01-18 | Wave Life Sciences Ltd | Composiciones de oligonucleotido y metodos de uso de las mismas. |
| WO2026077951A1 (en) | 2024-10-07 | 2026-04-16 | Vico Therapeutics B.V. | Improved aon for rna editing |
| WO2026096688A1 (en) * | 2024-10-30 | 2026-05-07 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| WO2026096689A1 (en) * | 2024-10-30 | 2026-05-07 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0821457D0 (en) * | 2008-11-24 | 2008-12-31 | Trillion Genomics Ltd | Oligonucleotides |
| WO2018041973A1 (en) * | 2016-09-01 | 2018-03-08 | Proqr Therapeutics Ii B.V. | Chemically modified single-stranded rna-editing oligonucleotides |
| EP3684378A4 (en) * | 2017-09-19 | 2021-06-16 | Children's National Medical Center | GAPMERS AND THEIR USES IN THE TREATMENT OF MUSCLE DYSTROPHY |
| CA3154768A1 (en) * | 2019-10-06 | 2021-04-15 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| US11434525B2 (en) * | 2020-08-06 | 2022-09-06 | Singular Genomics Systems, Inc. | Spatial sequencing |
-
2023
- 2023-05-12 CN CN202380049997.7A patent/CN119452084A/zh active Pending
- 2023-05-12 AU AU2023268503A patent/AU2023268503A1/en active Pending
- 2023-05-12 EP EP23804360.8A patent/EP4522744A1/en active Pending
- 2023-05-12 CA CA3253279A patent/CA3253279A1/en active Pending
- 2023-05-12 WO PCT/US2023/022142 patent/WO2023220440A1/en not_active Ceased
- 2023-05-12 US US18/864,860 patent/US20250302995A1/en active Pending
- 2023-05-12 JP JP2024566662A patent/JP2025516659A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023548584A5 (cg-RX-API-DMAC10.html) | ||
| ES2376507T3 (es) | An�?logos de �?cido nucleico bic�?clicos 6-disustituidos. | |
| RU2115658C1 (ru) | Гибридный олигонуклеотид, содержащий фосфоротиоатную и/или фосфородитиоатную связи, терапевтическая фармацевтическая композиция, способ ингибирования генной экспрессии | |
| CN103003288B (zh) | 具有修饰的亚基间键和/或端基的寡核苷酸类似物 | |
| KR100875003B1 (ko) | 누클레오시드의 위치 변형에 의한 올리고누클레오티드 CpG 매개성 면역 자극의 조절 | |
| ES2320315T3 (es) | Oligonucleotidos inmunoestimuladores. | |
| ES2268736T3 (es) | Moleculas de acido nucleico inmunoestimulantes. | |
| CA2808233C (en) | Aptamers to 4-1bb and their use in treating diseases and disorders | |
| EP0680969B1 (de) | Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung | |
| JP2023109824A (ja) | GalNAc誘導体 | |
| JP2022551124A5 (cg-RX-API-DMAC10.html) | ||
| KR101807324B1 (ko) | 다운 증후군 유전자에 대한 천연 안티센스 전사체의 억제에 의한 다운 증후군 유전자 관련된 질환의 치료 | |
| EP0710667A2 (de) | Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung | |
| JP2010536792A (ja) | テトラヒドロピラン核酸類似体 | |
| CN1118140A (zh) | 为提高在酸性pH的稳定性而改性的低聚核苷酸 | |
| WO2011159328A1 (en) | Methods of treatment using tlr7 and/or tlr9 inhibitors | |
| JP2018162245A (ja) | 三環式ヌクレオシド及びそれから調製されるオリゴマー化合物 | |
| KR101898177B1 (ko) | 톨-유사 수용체 기반 면역 반응을 조절하기 위한 면역 조절 올리고누클레오티드 (iro) 화합물 | |
| TW201825103A (zh) | 經修飾之寡核苷酸及使用方法 | |
| JP2017528441A5 (cg-RX-API-DMAC10.html) | ||
| JP2007510405A5 (cg-RX-API-DMAC10.html) | ||
| JP2018109015A (ja) | 三環ヌクレオシドおよびこれらから調製したオリゴマー化合物 | |
| JP2011515357A5 (cg-RX-API-DMAC10.html) | ||
| JP2022552192A (ja) | レチノイン酸誘導遺伝子iタンパク質に結合する核酸化合物 | |
| JP2007527246A (ja) | ヒトil−12サイトカインファミリーに対するアプタマーおよび自己免疫疾患の治療剤としてのそれらの使用 |